10-QPeriod: Q2 FY2006

DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2006

Filed July 21, 2006For Securities:DXCM

Summary

DexCom, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2006. As this is an early-stage filing (the company was not a large accelerated or accelerated filer at this time), investors should note that the report details the company's financial position and operational results, but may lack the extensive operational history and established trends seen in more mature companies. The focus of this filing will be on the company's revenue generation, cost structure, and cash flow from its core operations in the rapidly evolving diabetes technology market. Investors should pay close attention to the "Management's Discussion and Analysis of Financial Condition and Results of Operations" (MD&A) section for insights into the company's performance drivers, challenges, and outlook. Given the nature of a medical device company, understanding research and development expenses, sales and marketing efforts, and regulatory hurdles will be critical. The balance sheet and cash flow statement will provide a clear picture of the company's liquidity and its ability to fund ongoing operations and future growth initiatives.

Key Highlights

  • 1DexCom, Inc. is filing its quarterly report for the period ended June 30, 2006, indicating its status as a non-accelerated filer.
  • 2The filing includes unaudited financial statements: Balance Sheets, Statements of Operations, and Statements of Cash Flows for relevant periods in 2005 and 2006.
  • 3Key sections for investor review include Item 2 (MD&A) and Item 1A (Risk Factors).
  • 4The report covers the financial performance and condition of DexCom, Inc. as it operates within the diabetes technology sector.
  • 5The company had 28,060,504 shares of common stock outstanding as of July 10, 2006.
  • 6This 10-Q filing provides the standard disclosures required by the SEC for ongoing public companies, including legal proceedings and controls and procedures.

Frequently Asked Questions

The financial health of DexCom as of June 30, 2006, can be assessed by reviewing the unaudited Balance Sheets, Statements of Operations, and Statements of Cash Flows included in Part I of the filing. Investors should examine the company's assets, liabilities, revenue, expenses, and cash flow activities to understand its financial position and performance during the reported periods.

The main risks facing DexCom are detailed in Item 1A, 'Risk Factors'. Investors should carefully read this section to understand potential challenges related to product development, market adoption, competition, regulatory approvals, and other operational or financial risks that could impact the company's future performance.

The Statements of Operations (unaudited) for the three and six months ended June 30, 2006, and 2005, will provide details on DexCom's revenue and profitability. Investors should analyze these statements to understand the company's top-line growth and its ability to manage costs and generate profits.

The Statements of Cash Flows (unaudited) for the six months ended June 30, 2006, and 2005, will indicate the company's cash flow generation from operating, investing, and financing activities. Investors should review this to determine if the core business operations are generating sufficient cash to support growth and operational needs.